Demirci Yildirim, Tuba http://orcid.org/0000-0003-3186-0591
Kahraman, Aslı http://orcid.org/0000-0001-5781-8506
Köken Avşar, Aydan http://orcid.org/0000-0003-4149-621X
Onen, Fatos http://orcid.org/0000-0002-6341-2622
Akar, Servet http://orcid.org/0000-0002-3734-1242
Sari, İsmail http://orcid.org/0000-0001-7737-4180
Funding for this research was provided by:
Pfizer (ID#68022735)
Article History
Received: 11 June 2023
Accepted: 2 August 2023
First Online: 10 August 2023
Declarations
:
: The authors report no conflicts of interest.
: The study was conducted in accordance with the Helsinki Declaration and was approved by the local ethics committee (IRB number: 0166). Written informed consent was obtained from all participants. It was also registered on clinicaltrials.gov with the number NCT04792957.
: The authors declare that the submitted work is their own and that copyright has not been breached in seeking its publication. This study was presented as an oral presentation during the EULAR 2022 European Congress of Rheumatology, held from June 1–4, 2022, in Denmark.